{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:29:33Z","timestamp":1784305773620,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102458","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:33:01Z","timestamp":1661301181000},"page":"102458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"110","author":[{"given":"Lucia","family":"Musacchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Amela","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tuninetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Giannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2022.102458_b0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102458_b0010","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102458_b0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102458_b0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102458_b0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102458_b0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a Phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102458_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low\u2010grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102458_b0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2022.102458_b0045","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"JCO"},{"issue":"10324","key":"10.1016\/j.ctrv.2022.102458_b0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102458_b0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102458_b0060","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2021.39.15_suppl.5519","article-title":"Molecular results and potential biomarkers identified from MILO\/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"39","author":"Grisham","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102458_b0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102458_b0070","first-page":"2235","article-title":"Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines","volume":"6","author":"Fern\u00e1ndez","year":"2016","journal-title":"Am J Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722200127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722200127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:09Z","timestamp":1759656489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722200127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":14,"alternative-id":["S030573722200127X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102458","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102458"}}